Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-50717 for Dyskinesia in Cerebral Palsy
NCT03813238Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in dyskinetic cerebral palsy (DCP) comparing TEV-50717 with Placebo (2 arms). Primary endpoint: Movement Disorder-Childhood Rating Scale Part II Total Score at Week 15. Started Aug 2019; status: completed.
02
Drugs
deutetrabenazine
03
Conditions
dyskinetic cerebral palsy (DCP)
Beyond the preview
Go deeper on NCT03813238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813238.